Artiva Biotherapeutics, Inc.

What they do

Artiva is a clinical-stage biotechnology company based in San Diego whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Its lead asset, AlloNK, is being studied in combination with rituximab, including in a Phase 2a basket trial in refractory autoimmune indications. The company presented clinical, safety and translational data for AlloNK at EULAR 2026 across refractory RA, Sjogren's disease (SjD) and systemic sclerosis (SSc).

Revenue drivers

• No product revenue — Artiva reported annual revenue of $0.00 in 2025 and $251,000 in 2024, with prior 2023 revenue of $32.9M; the company is clinical-stage and has no approved product.
• AlloNK plus rituximab in refractory RA — The lead program is moving into a Phase 3 registrational randomized controlled trial in approximately 150 refractory RA patients, but it does not yet generate revenue.
• AlloNK in additional autoimmune indications — SjD and SSc are being explored in the Phase 2a basket trial, with no revenue contribution to date.

Recent performance

Artiva reported second quarter 2026 financial results on August 6, 2026, with cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029. In the company-sponsored Phase 2a basket trial, five of seven patients (71%) with six months of follow-up achieved an ACR50 response as of the April 3, 2026 data cutoff. Among 55 safety-evaluable autoimmune patients treated with AlloNK plus rituximab, no CRS, ICANS, AlloNK-related serious adverse events or treatment discontinuations due to adverse events were observed. The company reported no revenue and continued operating losses, consistent with its clinical-stage status.

Strategy

Artiva is initiating a Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026. The company received FDA RMAT designation for AlloNK plus rituximab in refractory RA, which supports its planned registrational strategy and access to expedited development and review mechanisms. Artiva raised approximately $300 million in an underwritten offering and states it is well capitalized to initiate and execute the planned Phase 3 trial and advance AlloNK across B-cell-driven autoimmune diseases. It also published a first peer-reviewed manuscript in Cytotherapy describing AlloNK's high-affinity CD16 158V/V phenotype and scalable GMP manufacturing.

Risks

• No product revenue and ongoing losses — Artiva reported $0.00 annual revenue in 2025 and net losses of $83.9 million in 2025, and will need to fund development from cash reserves and financing.
• Clinical trial risk — The Phase 3 registrational trial in refractory RA is planned to begin in the second half of 2026 and may not replicate the Phase 2a ACR50 results or achieve its endpoints.
• Regulatory and approval uncertainty — RMAT designation for AlloNK plus rituximab in refractory RA does not guarantee FDA approval, and the registrational strategy remains subject to review.
• Cash burn and dilution — Operating cash flow was negative $76.8 million in 2025, and the company may need additional capital if operations extend beyond the projected 2029 funding runway.

Outlook

Management states that cash, cash equivalents and investments of $349.4 million as of June 30, 2026 are expected to fund operations into 2029. Artiva plans to initiate a Phase 3 registrational randomized controlled trial in approximately 150 refractory RA patients in the second half of 2026. The company intends to continue advancing AlloNK across B-cell-driven autoimmune diseases, supported by RMAT designation and FDA alignment on the Phase 3 design.